---
title: åŠ å·´å–·ä¸
description: 
published: true
date: 2026-01-30T09:38:28.608Z
tags: 
editor: markdown
dateCreated: 2026-01-30T05:57:25.516Z
---

[â—€è¿”å›](/è¯ç‰©/home.md)

# åŠ å·´å–·ä¸



**åŠ å·´å–·ä¸(Gabapentin)**ï¼ˆä¹Ÿç§°ä¸º **Neurontin**ï¼‰æ˜¯[åŠ å·´å–·ä¸ç±»](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/åŠ å·´å–·ä¸ç±»ç‰©è´¨.md)[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ç±»ç‰©è´¨ã€‚å®ƒæ˜¯ç¥ç»é€’è´¨[GABA](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)çš„ç»“æ„ç±»ä¼¼ç‰©ï¼Œé€šè¿‡æŠ‘åˆ¶å¤§è„‘ä¸­çš„æŸäº›é’™é€šé“ï¼Œå³å«æœ‰ $\alpha_{2}\delta$ äºšåŸºçš„ç”µå‹ä¾èµ–æ€§é’™é€šé“ï¼ˆVGCCï¼‰èµ·ä½œç”¨ã€‚[\[3\]](#cite_note-CalandreRico-Villademoros2016-3)

åŠ å·´å–·ä¸æœ€åˆæ˜¯ä¸ºäº†æ²»ç–—ç™«ç—«è€Œå¼€å‘çš„ï¼Œç›®å‰å·²è¢«FDAæ‰¹å‡†ç”¨äºæ²»ç–—æˆäººçš„å¸¦çŠ¶ç–±ç–¹åç¥ç»ç—›ï¼Œå¹¶ä½œä¸ºéƒ¨åˆ†å‘ä½œæ€§ç™«ç—«çš„è¾…åŠ©æ²»ç–—ã€‚å®ƒç»å¸¸è¢«è¶…é€‚åº”ç—‡ç”¨äºæ²»ç–—[ä¸å®è…¿](/è¯æ•ˆ/ä¸å®è…¿.md)ã€ç¤¾äº¤ç„¦è™‘ç—‡ã€ææ…Œç—‡å’Œå¹¿æ³›æ€§ç„¦è™‘ç—‡ã€‚[\[4\]](#cite_note-4)[\[5\]](#cite_note-5)[\[6\]](#cite_note-6)

ç„¶è€Œï¼ŒåŠ å·´å–·ä¸æ²»ç–—ç„¦è™‘ç—‡çš„ç–—æ•ˆå°šä¸æ˜ç¡®ï¼Œè¯æ®"æœ‰äº›æ··æ‚"ã€‚[\[7\]](#cite_note-7)[\[8\]](#cite_note-8)[\[9\]](#cite_note-9)[\[10\]](#cite_note-10) å®ƒæ˜¯æ²»ç–—ç³–å°¿ç—…æ€§ç¥ç»ç—…å˜ã€å¸¦çŠ¶ç–±ç–¹åç¥ç»ç—›å’Œä¸­æ¢ç¥ç»ç—›å¼•èµ·çš„ç¥ç»æ€§ç–¼ç—›çš„ä¸€çº¿æ¨èè¯ç‰©ã€‚[\[11\]](#cite_note-11)

[ä¸»è§‚æ•ˆåº”](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md#ä¸»è§‚æ•ˆåº”)åŒ…æ‹¬è½»åº¦è‡³ä¸­åº¦çš„[ç„¦è™‘æŠ‘åˆ¶](/è¯æ•ˆ/é•‡é™.md)ã€[é•‡ç—›](/è¯æ•ˆ/é•‡ç—›.md)å’Œ[è‚Œè‚‰æ¾å¼›](/è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)ã€‚å…¶é•‡ç—›å’ŒæŠ—ç„¦è™‘ä½œç”¨ä½¿åŠ å·´å–·ä¸å…·æœ‰ä¸€å®šçš„å¨±ä¹æ½œåŠ›ï¼Œå…¶æ–¹å¼å¯ä¸æ¸©å’Œçš„[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ç›¸åª²ç¾ã€‚ç„¶è€Œï¼Œæ®æŠ¥é“ï¼Œéšç€é‡å¤ä½¿ç”¨ï¼Œè¿™äº›å¨±ä¹æ•ˆæœä¼šè¿…é€Ÿå‡å¼±ï¼Œå¹¶ä¸”é€šå¸¸æ˜¯ç”±å¯¹è¯¥åŒ–åˆç‰©æ²¡æœ‰è€å—æ€§çš„äººæŠ¥å‘Šçš„ã€‚

ä¸å¤§å¤šæ•°å¨±ä¹æ€§[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ç›¸æ¯”ï¼ŒåŠ å·´å–·ä¸è¢«è®¤ä¸ºå…·æœ‰è¾ƒä½çš„æ»¥ç”¨æ½œåŠ›ã€‚ç„¶è€Œï¼Œé•¿æœŸä½¿ç”¨ä¼šå¯¼è‡´èº«ä½“ä¾èµ–ã€‚æ­¤å¤–ï¼Œå½“å®ƒä¸å…¶ä»–[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)è”ç”¨æ—¶ï¼Œè‡´å‘½[è¯ç‰©è¿‡é‡](/æ–‡æ¡£/è¯ç‰©è¿‡é‡.md)çš„é£é™©ä¼šå¢åŠ ï¼ˆè€ƒè™‘åˆ°å…¶è¾ƒå¼±çš„æ•ˆæœï¼Œè¿™æ˜¯ä¸€ç§æœ‰äº›å¸¸è§çš„åšæ³•ï¼‰ã€‚å¦‚æœä½¿ç”¨è¯¥ç‰©è´¨ï¼Œå¼ºçƒˆå»ºè®®é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚

**å½“[åŠ å·´å–·ä¸ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/åŠ å·´å–·ä¸ç±»ç‰©è´¨.md)ä¸å…¶ä»–[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)å¦‚[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)ã€[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ã€[å·´æ¯”å¦¥ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±»ç‰©è´¨.md)ã€[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)ã€[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)æˆ–å…¶ä»–[GABAèƒ½ç‰©è´¨](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)è”ç”¨æ—¶ï¼Œå¯èƒ½ä¼šå‘ç”Ÿè‡´å‘½çš„[è¯ç‰©è¿‡é‡](/æ–‡æ¡£/è¯ç‰©è¿‡é‡.md)ã€‚[\[1\]](#cite_note-tripsit-1)**

å¼ºçƒˆä¸å»ºè®®è”ç”¨è¿™äº›ç‰©è´¨ï¼Œç‰¹åˆ«æ˜¯åœ¨[ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md)åˆ°[ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md)å‰‚é‡ä¸‹ã€‚

---

| åŠ å·´å–·ä¸ | |
| --- | --- |
| [![Gabapentin.png](/æ–‡ä»¶/Gabapentin.png)](/æ–‡ä»¶/Gabapentin.png) | |
| **åŒ–å­¦å‘½å** | |
| é€šç”¨åç§° | *Gabapentin, Neurontin, Gabarone, Gralise* |
| å–ä»£åç§° | *Gabapentin* |
| ç³»ç»Ÿå‘½å | *1\-(Aminomethyl)cyclohexaneacetic acid* |
| **åˆ†ç±»** | |
| ç²¾ç¥ä½œç”¨åˆ†ç±» | *[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)* |
| åŒ–å­¦åˆ†ç±» | *[åŠ å·´å–·ä¸ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/åŠ å·´å–·ä¸ç±»ç‰©è´¨.md)* |
| **[ç»™è¯é€”å¾„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | |
| **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»è¾ƒä½å‰‚é‡å¼€å§‹ã€‚[å‚è§è´Ÿè´£ä»»çš„ç”¨è¯éƒ¨åˆ†](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚ | |
| **[å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | |
| [å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) | |
| [ç”Ÿç‰©åˆ©ç”¨åº¦](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) | 27% \- 60%[\[2\]](#cite_note-NeurotoninMedScape-2) |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 200 mg |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 200 \- 900 mg |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 900 \- 1500 mg |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 1500 \- 2400 mg |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md) | 2400 mg \+ |
| **[è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)** | |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 6 \- 10 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 30 \- 120 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md) | 120 \- 180 åˆ†é’Ÿ |
| **[å…è´£å£°æ˜](/æ–‡æ¡£/å…³äºæœ¬ç«™/è§‚å‰æé†’.md)ï¼š** æœ¬ç«™çš„[å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md)ä¿¡æ¯æ¥æºäºç”¨æˆ·å’Œ[ç½‘ç»œ](/æ–‡æ¡£/æ•™å­¦ç´¢å¼•é¡µ.md)ï¼Œä»…ä¾›æ•™è‚²ç›®çš„ã€‚è¿™å°±ä¸æ˜¯æ¨èï¼Œåº”å‘å…¶ä»–æ¥æºæ ¸å®å‡†ç¡®æ€§ã€‚ | |
| **[è¯ç‰©è”ç”¨](#Dangerous_interactions)** | |
| [é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md) | ğŸ’” è”ç”¨å±é™© |
| [æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) | âš ï¸ è°¨æ…è”ç”¨ |

---

## ç›®å½•

* [1 åŒ–å­¦](#Chemistry)
* [2 è¯ç†å­¦](#Pharmacology)
* [3 ä¸»è§‚æ•ˆåº”](#Subjective_effects)
    + [3.1 **èº¯ä½“æ•ˆåº”**](#Physical_effects)
    + [3.2 **è®¤çŸ¥æ•ˆåº”**](#Cognitive_effects)
    + [3.3 **è§†è§‰æ•ˆåº”**](#Visual_effects)
        - [3.3.1 å¹»è§‰çŠ¶æ€](#Hallucinatory_states)
        - [3.3.2 åˆ†ç¦»æ•ˆåº”](#Disconnective_effects)
    + [3.4 ä½“éªŒæŠ¥å‘Š](#Experience_reports)
* [4 æ¯’æ€§å’Œä¼¤å®³æ½œåŠ›](#Toxicity_and_harm_potential)
    + [4.1 è‡ªæ€](#Suicide)
    + [4.2 è‡´æ­»å‰‚é‡](#Lethal_dosage)
    + [4.3 ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ›](#Dependence_and_abuse_potential)
    + [4.4 å±é™©çš„ç›¸äº’ä½œç”¨](#Dangerous_interactions)
* [5 æ³•å¾‹åœ°ä½](#Legal_status)
* [6 å¦è§](#See_also)
* [7 å¤–éƒ¨é“¾æ¥](#External_links)
* [8 å‚è€ƒæ–‡çŒ®](#References)

## åŒ–å­¦ {#Chemistry}

åŠ å·´å–·ä¸æ˜¯ GABA çš„ 3,3-äºŒå–ä»£è¡ç”Ÿç‰©ã€‚å› æ­¤ï¼Œå®ƒæ˜¯ä¸€ç§ GABA ç±»ä¼¼ç‰©ï¼Œä¹Ÿæ˜¯ä¸€ç§ Î³-æ°¨åŸºé…¸ã€‚[\[12\]](#cite_note-12) å…·ä½“æ¥è¯´ï¼Œå®ƒæ˜¯ GABA çš„è¡ç”Ÿç‰©ï¼Œåœ¨ 3 ä½æœ‰ä¸€ä¸ªæˆŠåŸºäºŒå–ä»£ï¼Œç”±æ­¤å¾—åâ€”â€”gaba*pentin*ï¼Œä»è€Œå½¢æˆä¸€ä¸ªå…­å…ƒç¯ã€‚å½¢æˆç¯åï¼ŒèƒºåŸºå’Œç¾§åŸºä¸å†åƒåœ¨ GABA ä¸­é‚£æ ·å¤„äºç›¸å¯¹ä½ç½®ï¼š[\[13\]](#cite_note-13) å®ƒä»¬çš„æ„è±¡æ›´åŠ å—é™ã€‚[\[14\]](#cite_note-14)

åŠ å·´å–·ä¸ï¼Œæˆ– 1-(æ°¨ç”²åŸº)ç¯å·±çƒ·ä¹™é…¸ï¼Œæ˜¯ç¥ç»é€’è´¨[GABA](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)çš„ç±»ä¼¼ç‰©ã€‚å®ƒåŒ…å«ä¸€ä¸ªç»“åˆåˆ°ç”²æ°¨åŸºé“¾ CH3NH2 çš„ç¯å·±çƒ·ç¯ã€‚åœ¨ç›¸åŒçš„ä½ç½® R1ï¼Œç¯å·±çƒ·ç¯ä¹Ÿè¢«ä¹™é…¸åŸºå›¢å–ä»£ã€‚åŠ å·´å–·ä¸åœ¨ç»“æ„ä¸Šç±»ä¼¼äº GABAã€‚GABA åŒ…å«ç»“åˆåˆ°ä¸é…¸é“¾æœ«ç«¯ç¢³çš„æ°¨åŸºã€‚åŠ å·´å–·ä¸çš„ç»“æ„åŒ…å« GABA ä¸é…¸é“¾çš„ä»²ç¢³ R3 å¹¶å…¥ç›¸è¿çš„ç¯å·±çƒ·ç¯ä¸­ï¼Œå°†å…¶è½¬åŒ–ä¸ºå”ç¢³ï¼ŒåŒæ—¶ä»ä¿æŒé“¾çŠ¶ç»“æ„ã€‚

## è¯ç†å­¦ {#Pharmacology}

åŠ å·´å–·ä¸è°ƒèŠ‚è°·æ°¨é…¸è„±ç¾§é…¶ (GAD) å’Œæ”¯é“¾æ°¨åŸºè½¬ç§»é…¶ (BCAT) çš„ä½œç”¨ï¼Œè¿™ä¸¤ç§é…¶å‚ä¸[GABA](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)çš„ç”Ÿç‰©åˆæˆã€‚åœ¨äººç±»å’Œå¤§é¼ çš„ç ”ç©¶ä¸­ï¼Œå‘ç°åŠ å·´å–·ä¸å¢åŠ  GABA çš„ç”Ÿç‰©åˆæˆï¼Œå¹¶åœ¨ä½“å¤–å¢åŠ éçªè§¦ GABA çš„ç¥ç»ä¼ é€’ã€‚[\[15\]](#cite_note-15) ç”±äº GABA ç³»ç»Ÿæ˜¯å¤§è„‘ä¸­æœ€ä¸ºä¸°å¯Œçš„æŠ‘åˆ¶æ€§å—ä½“ç»„ï¼Œå…¶ç”Ÿç‰©åˆæˆçš„å¢åŠ å¯¼è‡´åŠ å·´å–·ä¸å¯¹ç¥ç»ç³»ç»Ÿäº§ç”Ÿ[é•‡é™](/è¯æ•ˆ/é•‡é™.md)å’Œ[æŠ—ç„¦è™‘](/è¯æ•ˆ/é•‡é™.md)ï¼ˆæˆ–[é•‡é™ä½œç”¨](/è¯æ•ˆ/é•‡é™.md)ï¼‰ã€‚

å¦ä¸€é¡¹åŸºäº 7 Tesla ç£å…±æŒ¯æˆåƒçš„ç ”ç©¶[\[16\]](#cite_note-16)è¯å®ï¼ŒåŠ å·´å–·ä¸ä¼¼ä¹åœ¨ä½“å†…æ€¥å‰§å¢åŠ è„‘å†… GABA æµ“åº¦ï¼Œæ¯”åŸºçº¿é«˜å‡ºè¾¾ 79%ã€‚

åŠ å·´å–·ä¸ä½œä¸ºä¸€ç§[åŠ å·´å–·ä¸ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/åŠ å·´å–·ä¸ç±»ç‰©è´¨.md)ï¼Œä¹Ÿè¢«è¯æ˜ç»“åˆåˆ°ç”µå‹é—¨æ§é’™é€šé“çš„ $\alpha_{2}\delta-1$ äºšåŸºï¼Œå……å½“ VGCC é˜»æ»å‰‚ï¼Œè¿™æœ‰åŠ©äºå…¶æŠ‘åˆ¶ã€é•‡ç—›å’ŒæŠ—ç„¦è™‘ä½œç”¨ã€‚[\[17\]](#cite_note-17) ç›®å‰å°šä¸ç¡®å®šè¿™ç§ä½œç”¨æ–¹å¼ç©¶ç«Ÿå¦‚ä½•ä¿ƒæˆåŠ å·´å–·ä¸çš„ç²¾ç¥æ´»æ€§æ•ˆåº”ã€‚

åŠ å·´å–·ä¸çš„ç”Ÿç‰©åˆ©ç”¨åº¦ç›¸å¯¹è¾ƒä½ï¼Œä¸”ä¸å‰‚é‡æˆåæ¯”ï¼ˆå³è¾ƒé«˜å‰‚é‡çš„ç”Ÿç‰©åˆ©ç”¨åº¦ä½äºè¾ƒä½å‰‚é‡ï¼‰ã€‚æœç”¨ 900ã€1200ã€2400ã€3600 å’Œ 4800 æ¯«å…‹/å¤©ï¼Œåˆ†æ¬¡æœç”¨ï¼Œæ¯ 8 å°æ—¶ä¸€ç²’åï¼ŒåŠ å·´å–·ä¸çš„ç”Ÿç‰©åˆ©ç”¨åº¦åˆ†åˆ«çº¦ä¸º 60%ã€47%ã€34%ã€33% å’Œ 27%ã€‚[\[18\]](#cite_note-18) åŠ å·´å–·ä¸å…·æœ‰é«˜åº¦äº²è„‚æ€§ï¼Œä½¿å¾—ä¸é¥±å’Œè„‚è‚ªå¦‚æ¤ç‰©æ²¹å’Œæ©„æ¦„æ²¹æ˜¾è‘—å¢åŠ æ€»å¸æ”¶é‡ã€‚è¿™æ„å‘³ç€åƒä¸€é¡¿é«˜è„‚è‚ªé¤ä¼šå¤§å¤§å¢åŠ åŠ å·´å–·ä¸çš„ç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œå› ä¸ºä¸é¥±å’Œè„‚è‚ªä¸åŠ å·´å–·ä¸ç»“åˆä»¥å…è®¸å¸æ”¶ï¼Œè€Œä¸”è¿›é¤ä¼šå‡æ…¢å¹¶é€šè¿‡å‡å°‘åŠ å·´å–·ä¸è½¬è¿è›‹ç™½çš„é¥±å’Œåº¦æ¥å¢åŠ åŠ å·´å–·ä¸çš„å¸æ”¶ã€‚[\[2\]](#cite_note-NeurotoninMedScape-2)

å½“åœ¨è¶³å¤ŸçŸ­çš„æ—¶é—´å†…æ¶ˆè€—è¶³å¤Ÿå¤§å‰‚é‡çš„åŠ å·´å–·ä¸ï¼Œå¯¼è‡´èº«ä½“æ— æ³•å†å¸æ”¶ä»»ä½•åŠ å·´å–·ä¸æ—¶ï¼Œå°±ä¼šå‘ç”ŸåŠ å·´å–·ä¸è½¬è¿è›‹ç™½é¥±å’Œï¼Œä»è€Œå¯¼è‡´ç”Ÿç‰©åˆ©ç”¨åº¦æ˜¾ç€é™ä½ï¼Œè¿™å¾ˆå¤§ç¨‹åº¦ä¸Šè§£é‡Šäº†éšç€å‰‚é‡å¢åŠ è€Œçœ‹åˆ°çš„ç”Ÿç‰©åˆ©ç”¨åº¦ä¸‹é™ã€‚

åŠ å·´å–·ä¸æ˜¯ç”µå‹é—¨æ§é’¾é€šé“ KCNQ3 å’Œ KCNQ5 çš„å¼ºæ•ˆæ¿€æ´»å‰‚ï¼Œå³ä½¿åœ¨ä½çº³æ‘©å°”æµ“åº¦ä¸‹ä¹Ÿæ˜¯å¦‚æ­¤ã€‚ç„¶è€Œï¼Œè¿™ç§æ¿€æ´»ä¸å¤ªå¯èƒ½æ˜¯åŠ å·´å–·ä¸æ²»ç–—æ•ˆæœçš„ä¸»è¦æœºåˆ¶ã€‚[\[19\]](#cite_note-19)

## ä¸»è§‚æ•ˆåº” {#Subjective_effects}

åŠ å·´å–·ä¸ç”Ÿç‰©åˆ©ç”¨åº¦ä¸‹é™çš„é—®é¢˜å¯ä»¥é€šè¿‡æ›´é¢‘ç¹åœ°æœç”¨è¾ƒä½å‰‚é‡è€Œä¸æ˜¯è¾ƒä¸é¢‘ç¹åœ°æœç”¨è¾ƒé«˜å‰‚é‡æ¥ç¼“è§£ã€‚ä½œä¸ºä¸€èˆ¬è§„åˆ™ï¼Œæ¯ 30-45 åˆ†é’Ÿä½¿ç”¨è¶…è¿‡ 250-300 æ¯«å…‹çš„åŠ å·´å–·ä¸å°†å¯¼è‡´æµªè´¹åŠ å·´å–·ä¸æ€»å‰‚é‡çš„å¾ˆå¤§ä¸€éƒ¨åˆ†ï¼Œå°½ç®¡è¿™ä¸ªæ•°å­—å› äººè€Œå¼‚ã€‚ç¢±æ€§ç¯å¢ƒä¼šæŠ‘åˆ¶åŠ å·´å–·ä¸çš„å¸æ”¶ï¼Œå› æ­¤ä½¿ç”¨é…¸æ€§ç‰©è´¨ï¼ˆå¦‚è½¯é¥®æ–™ï¼‰é™ä½èƒƒçš„ pH å€¼ä¹Ÿä¼šæé«˜ç”Ÿç‰©åˆ©ç”¨åº¦ã€‚ä¸€èˆ¬ä¸å»ºè®®åœ¨æœç”¨åŠ å·´å–·ä¸å‰å 2 å°æ—¶å†…æœç”¨æŠ—é…¸å‰‚ï¼Œå› ä¸ºè™½ç„¶ä¸å±é™©ï¼Œä½†ä¼šä¸¥é‡é™ä½åŠ å·´å–·ä¸çš„æ€»å¸æ”¶ã€‚[\[20\]](#cite_note-20)

***å…è´£å£°æ˜ï¼š** ä¸‹é¢åˆ—å‡ºçš„æ•ˆåº”å¼•ç”¨äº†[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md#ä¸»è§‚æ•ˆåº”) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºè½¶äº‹ç”¨æˆ·æŠ¥å‘Šå’Œ[FreeODwiki](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md)è´¡çŒ®è€…ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”å¸¦ç€å¥åº·çš„æ€€ç–‘æ€åº¦æ¥çœ‹å¾…å®ƒä»¬ã€‚*

*å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”å¹¶ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚*åŒæ ·ï¼Œ**ä¸è‰¯ååº”**éšç€å‰‚é‡çš„å¢åŠ å˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡*** â˜ ã€‚

### **èº¯ä½“æ•ˆåº”** ![Child.png](/æ–‡ä»¶/Child.png)

*   **[é•‡é™](/è¯æ•ˆ/é•‡é™.md)** - åŠ å·´å–·ä¸é€šå¸¸å…·æœ‰è½»å¾®çš„é•‡é™ä½œç”¨ï¼Œå¯èƒ½ä¼šå¯¼è‡´å—œç¡çŠ¶æ€ã€‚åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå¯èƒ½ä¼šå¯¼è‡´ä¸­åº¦é•‡é™çŠ¶æ€ã€‚
*   **[é£Ÿæ¬²å¢å¼º](/è¯æ•ˆ/é£Ÿæ¬²å¢å¼º.md)** - é£Ÿæ¬²å¢å¼ºå¹¶ä¸ç‰¹åˆ«æ˜¾è‘—ï¼Œä½†æœ‰æ—¶ä¼šè¢«æŠ¥é“ã€‚å½“ä¸[å¤§éº»](/è¯ç‰©/å¤§éº».md)è”ç”¨æ—¶ï¼Œå®ƒä¼šæœ‰ååŒä½œç”¨ã€‚
*   **[è‚Œè‚‰æ¾å¼›](/è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)** - åŠ å·´å–·ä¸å…·æœ‰è‚Œè‚‰æ¾å¼›ä½œç”¨ï¼Œå°½ç®¡ç¨‹åº¦ä¸åŠ[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ã€[å·´æ¯”å¦¥ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±»ç‰©è´¨.md)æˆ–[GHB](/è¯ç‰©/GHB.md)ã€‚
*   **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)** - åŠ å·´å–·ä¸èƒ½å¤Ÿåœ¨ä¸€äº›ä½¿ç”¨è€…ä¸­äº§ç”Ÿè½»å¾®åˆ°ä¸­åº¦çš„èº¯ä½“æ¬£å¿«æ„Ÿã€‚ç„¶è€Œï¼Œä¸å…¶ä»–[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ï¼ˆä¾‹å¦‚[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ã€[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)å’Œ[GHB](/è¯ç‰©/GHB.md)ï¼‰ç›¸æ¯”ï¼Œè¿™æ˜¯éå¸¸ä¸ä¸€è‡´çš„ï¼Œå¹¶ä¸”è€å—æ€§å»ºç«‹è¿…é€Ÿã€‚å› æ­¤ï¼Œå®ƒè¢«è®¤ä¸ºæ˜¯ä¸€ç§è¾ƒå·®çš„è‡´æ¬£å¿«å‰‚ã€‚
*   **[æ€§æ¬²å‡é€€](/è¯æ•ˆ/æ€§æ¬²å‡é€€.md)** - è®¸å¤šä½¿ç”¨è€…æ³¨æ„åˆ°æœç”¨åŠ å·´å–·ä¸æ—¶æ€§æ¬²æ˜æ˜¾ä¸‹é™ã€‚è¿™åœ¨å¨±ä¹æ€§ä½¿ç”¨æˆ–æŒ‰å¤„æ–¹æœç”¨æ—¶éƒ½å¯èƒ½å‘ç”Ÿã€‚
*   **[èº¯ä½“è½»ç›ˆæ„Ÿ](/è¯æ•ˆ/èº¯ä½“è½»ç›ˆæ„Ÿ.md)** - ä¸€äº›ä½¿ç”¨è€…æŠ¥å‘Šåœ¨éå¸¸é«˜çš„å‰‚é‡ä¸‹æ„Ÿè§‰æ›´è½»ã€‚
*   **[å¤´æ™•](/è¯æ•ˆ/å¤´æ™•.md)** - å¤´æ™•åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å¾ˆæ™®éï¼Œå°½ç®¡è®¸å¤šä½¿ç”¨è€…æŠ¥å‘Šè¯´è¿™å¹¶ä¸ä¸€å®šä»¤äººç—›è‹¦ã€‚ç„¶è€Œï¼Œä½¿ç”¨è€…åœ¨ä¸‹å¡æˆ–ä¸‹æ¥¼æ¢¯æ—¶åº”å°å¿ƒä¸è¦æ»‘å€’ã€‚
*   **[ç™«ç—«å‘ä½œæŠ‘åˆ¶](/è¯æ•ˆ/ç™«ç—«å‘ä½œæŠ‘åˆ¶.md)** - åŠ å·´å–·ä¸é€šå¸¸ç”¨ä½œæŠ—æƒŠå¥è¯ã€‚å½“ç”¨äºæ²»ç–—ç™«ç—«å’Œå…¶ä»–ç™«ç—«ç–¾ç—…æ—¶ï¼Œå®ƒé€šå¸¸ä¸å…¶ä»–æŠ—æƒŠå¥è¯è”ç”¨ã€‚
*   **[é•‡ç—›](/è¯æ•ˆ/é•‡ç—›.md)** - åŠ å·´å–·ä¸ç”¨äºæ§åˆ¶ç–¼ç—›ï¼Œç‰¹åˆ«æ˜¯çº¤ç»´è‚Œç—›/ç¥ç»æ€§ç–¼ç—›ï¼ˆç¥ç»ç—›ï¼‰å’Œ[ä¸å®è…¿](/è¯æ•ˆ/ä¸å®è…¿.md)ã€‚äººä»¬æ™®éè®¤ä¸ºå®ƒå¯¹æ€¥æ€§ç–¼ç—›çš„æ²»ç–—æ•ˆæœä¸å¦‚[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)ã€‚
*   **[è‚Œè‚‰é¢¤åŠ¨](/è¯æ•ˆ/è‚Œè‚‰é¢¤åŠ¨.md)**
*   **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)**

### **è®¤çŸ¥æ•ˆåº”** ![User.png](/æ–‡ä»¶/User.png)

*   **[åˆ†ææŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[ç„¦è™‘æŠ‘åˆ¶](/è¯æ•ˆ/é•‡é™.md)**
*   **[æ¢¦å¢ƒå¢å¼º](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/ä¿ƒæ¢¦å‰‚.md)**
*   **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[è®¤çŸ¥æ¬£å¿«](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[æƒ…æ„ŸæŠ‘åˆ¶](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)**
*   **[äººæ ¼è§£ä½“](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)** *å’Œ* **[ç°å®è§£ä½“](/è¯æ•ˆ/åˆ†ç¦»æ•ˆåº”.md)** - åœ¨éå¸¸é«˜çš„å‰‚é‡ä¸‹ï¼ŒåŠ å·´å–·ä¸å¯ä»¥è¯±å¯¼è½»å¾®çš„è§£ç¦»çŠ¶æ€ã€‚
*   **[å¥å¿˜](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** - ä¸å…¶ä»–[GABAèƒ½](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)è¯ç‰©ï¼ˆå¦‚[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ï¼‰ç›¸æ¯”ï¼ŒåŠ å·´å–·ä¸å¼•èµ·çš„å¥å¿˜ç¨‹åº¦è¦ä½å¾—å¤šã€‚
*   **[å—œç¡](/è¯æ•ˆ/é•‡é™.md)**
*   **[è‡ªæ€æ„å¿µ](/è¯æ•ˆ/è‡ªæ€æ„å¿µ.md)**[\[21\]](#cite_note-Patorno2010-21)

### **è§†è§‰æ•ˆåº”** {#Visual_effects}

#### å¹»è§‰çŠ¶æ€ {#Hallucinatory_states}
*   **[é—­çœ¼å¹»è§‰](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)** - åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œä¸€äº›ä½¿ç”¨è€…æŠ¥å‘Šæœ‰è½»å¾®åˆ°å¼ºçƒˆçš„é—­çœ¼è§†è§‰ (CEV)ã€‚è¿™äº›å¯èƒ½åŒ…æ‹¬ä½†ä¸é™äºç±»ä¼¼[è¿·å¹»](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è¿·å¹»å‰‚.md)çš„å‡ ä½•å›¾å½¢å’Œé£æ™¯ã€‚æ®æŒ‡å‡ºï¼ŒæŠ½å¸[å¤§éº»](/è¯ç‰©/å¤§éº».md)ä¼šå¤§å¤§å¢å¼ºè¿™äº›æ•ˆæœã€‚

#### åˆ†ç¦»æ•ˆåº” {#Disconnective_effects}
*   **[è§†è§‰åˆ†ç¦»](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)** - è¿™ç§æ•ˆæœé€šå¸¸éå¸¸æ¸©å’Œï¼Œåœ¨éå¸¸é«˜çš„å‰‚é‡ä¸‹ä¸ä¸€è‡´åœ°å‡ºç°ã€‚å®ƒå¯¼è‡´æ„Ÿè§‰å¥½åƒä¸€ä¸ªäººçš„è§†è§‰æ˜¯é¥è¿œçš„æˆ–æ¨¡ç³Šçš„ï¼Œå¹¶ä¸”æ˜¯é€šè¿‡å±å¹•æˆ–çª—æˆ·è§‚çœ‹çš„ã€‚ç„¶è€Œï¼Œå®ƒæ— æ³•åƒä¼ ç»Ÿçš„[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)é‚£æ ·äº§ç”Ÿ[å­”æ´ã€ç©ºé—´å’Œè™šç©º](/è¯æ•ˆ/è§†è§‰æ•ˆåº”.md)æˆ–æ›´é«˜æ°´å¹³çš„è§†è§‰åˆ†ç¦»ã€‚

### ä½“éªŒæŠ¥å‘Š {#Experience_reports}

æè¿°è¯¥åŒ–åˆç‰©åœ¨æˆ‘ä»¬[ä½“éªŒç´¢å¼•](/æ–‡æ¡£/æ•™å­¦ç´¢å¼•é¡µ.md)ä¸­çš„æ•ˆåº”çš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

*   [ä½“éªŒ:2100 mg åŠ å·´å–·ä¸ (å£æœ) - ç‚¹å¤´çŒç¡](/æŠ¥å‘Š/psychounautwiki/Experience:_2100_mg_Gabapentin_(Oral)_-_Nodding_Off.md)
*   [ä½“éªŒ:1.2 g åŠ å·´å–·ä¸, é…’ç²¾, å’ŒåŠç‰‡ 150 mg æ€¡è¯ºæ€ XR - å¯¹ç¤¾äº¤å’Œå‚»ç¬‘éå¸¸å¯çˆ±](/æŠ¥å‘Š/psychounautwiki/Experience:1.2_g_gabapentin,_alcohol,_and_half_of_150_mg_Effexor_XR_-_Pretty_lovely_for_socializing_and_giggles.md)
*   [ä½“éªŒ:7500mg - åŠ å·´å–·ä¸åˆ†æ](/æŠ¥å‘Š/psychounautwiki/Experience:7500mg_-_Analysis_of_gabapentin.md)
*   [ä½“éªŒ:æ›²é©¬å¤š, æ°¯ç¡è¥¿æ³®, åŠ å·´å–·ä¸, å’ŒèŒ¶è‹¯æµ·æ˜çš„è”ç”¨](/æŠ¥å‘Š/psychounautwiki/Experience:A_combination_of_tramadol,_clonazepam,_gabapentin,_and_dimenhydrinate.md)
*   [ä½“éªŒ:åŠ å·´å–·ä¸ (2100mg, å£æœ) - 2100mg åŠ å·´å–·ä¸](/æŠ¥å‘Š/psychounautwiki/Experience:Gabapentin_(2100mg,_Oral)_-_2100mg_of_Gabapentin.md)

å…¶ä»–ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

*   [Erowid Experience Vaults: Gabapentin](https://www.erowid.org/experiences/subs/exp_Pharms_Gabapentin.shtml)

## æ¯’æ€§å’Œä¼¤å®³æ½œåŠ› {#Toxicity_and_harm_potential}

**æ¯’æ€§å’Œä¼¤å®³æ½œåŠ›éƒ¨åˆ†æ˜¯ä¸€ä¸ª[å°ä½œå“](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md)ã€‚** å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´ç”šè‡³**å±é™©çš„é”™è¯¯**ä¿¡æ¯ï¼ä½ å¯ä»¥é€šè¿‡[æ‰©å±•æˆ–çº æ­£å®ƒ](CONTRIBUTING.md)æ¥æä¾›å¸®åŠ©ã€‚
*æ³¨æ„ï¼šå¦‚æœä½¿ç”¨è¿™ç§ç‰©è´¨ï¼Œè¯·åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶å¹¶ä½¿ç”¨**[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)**ã€‚*

[![](/æ–‡ä»¶/Gabapentin_FDA_prescription_document.jpg)](/æ–‡ä»¶/Gabapentin_FDA_prescription_document.jpg)

è¿™ä»½éšå¤„æ–¹åŠ å·´å–·ä¸æä¾›çš„æ–‡ä»¶åŒ…å«æœ‰å…³å…¶æ¯’æ€§å’Œä¼¤å®³æ½œåŠ›çš„è¯¦ç»†ä¿¡æ¯ã€‚

ç›¸å¯¹äºå‰‚é‡ï¼ŒåŠ å·´å–·ä¸çš„æ¯’æ€§è¾ƒä½ã€‚æˆäººæ‚£è€…æœç”¨åŠ å·´å–·ä¸æœ€å¸¸è§çš„å‰¯ä½œç”¨åŒ…æ‹¬å¤´æ™•ã€ç–²åŠ³ã€å—œç¡ã€ä½“é‡å¢åŠ å’Œå‘¨å›´æ°´è‚¿ï¼ˆå››è‚¢è‚¿èƒ€ï¼‰ã€‚[\[22\]](#cite_note-22) åŠ å·´å–·ä¸è¿˜å¯èƒ½å¯¼è‡´ä¸€äº›æ‚£è€…å‡ºç°æ€§åŠŸèƒ½éšœç¢ï¼Œç—‡çŠ¶å¯èƒ½åŒ…æ‹¬æ€§æ¬²ä¸§å¤±ã€æ— æ³•è¾¾åˆ°é«˜æ½®å’Œå‹ƒèµ·åŠŸèƒ½éšœç¢ã€‚[\[23\]](#cite_note-23) ç”±äºå¯èƒ½å‘ç”Ÿè“„ç§¯å’Œæ¯’æ€§ï¼Œè‚¾åŠŸèƒ½ä¸å…¨æ‚£è€…åº”æ…ç”¨åŠ å·´å–·ä¸ã€‚[\[24\]](#cite_note-24)

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¿™ç§è¯ç‰©æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚

### è‡ªæ€ {#Suicide}

2009å¹´ï¼Œç¾å›½é£Ÿå“å’Œè¯ç‰©ç®¡ç†å±€å‘å¸ƒè­¦å‘Šï¼Œç§°æœç”¨åŠ å·´å–·ä¸ï¼ˆä»¥åŠå…¶ä»–[æŠ—æƒŠå¥è¯](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ï¼‰çš„æ‚£è€…æŠ‘éƒã€è‡ªæ€å¿µå¤´å’Œè¡Œä¸ºçš„é£é™©å¢åŠ ï¼Œ[\[25\]](#cite_note-25) å¹¶ä¿®æ”¹äº†åŒ…è£…è¯´æ˜ä¹¦ä»¥åæ˜ è¿™ä¸€ç‚¹ã€‚2010 å¹´çš„ä¸€é¡¹èŸèƒåˆ†æè¯å®äº†ä¸ä½¿ç”¨åŠ å·´å–·ä¸ç›¸å…³çš„è‡ªæ€é£é™©å¢åŠ ã€‚[\[21\]](#cite_note-Patorno2010-21)

2010å¹´ï¼ŒPatorno E, Bohn RL, Wahl PM ç­‰äººè¿›è¡Œçš„ä¸€é¡¹ç ”ç©¶å‘ç°ï¼Œä¸ä½¿ç”¨[æ‰˜å¡é…¯](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ç›¸æ¯”ï¼Œä½¿ç”¨åŠ å·´å–·ä¸å¯èƒ½ä¸è‡ªæ€è¡Œä¸ºå’Œ/æˆ–æš´åŠ›æ­»äº¡çš„å¢åŠ æœ‰å…³ã€‚[\[26\]](#cite_note-26)

åº”è¯¥æ³¨æ„çš„æ˜¯ï¼Œåœ¨è¿™ä¸¤é¡¹ç ”ç©¶ä»¥åŠå…¶ä»–ç ”ç©¶ä¸­ï¼Œè¯„ä¼°çš„æ‚£è€…å…·æœ‰è¾ƒé«˜çš„è‡ªæ€é£é™©ï¼Œå¹¶ä¸”ç ”ç©¶æ—¢æœ‰é™åˆä¸ç²¾ç¡®ã€‚[\[21\]](#cite_note-Patorno2010-21)

### è‡´æ­»å‰‚é‡ {#Lethal_dosage}

æ„å¤–æˆ–æ•…æ„[è¯ç‰©è¿‡é‡](/æ–‡æ¡£/è¯ç‰©è¿‡é‡.md)çš„äººå¯èƒ½ä¼šå‡ºç°å—œç¡ã€é•‡é™ã€è§†åŠ›æ¨¡ç³Šã€å£é½¿ä¸æ¸…ã€å—œç¡ç”šè‡³æ­»äº¡ï¼ˆå¦‚æœæœç”¨é‡éå¸¸å¤§ï¼Œç‰¹åˆ«æ˜¯å¦‚æœä¸é…’ç²¾è”ç”¨ï¼‰ã€‚å¯ä»¥æµ‹é‡è¡€æ¸…åŠ å·´å–·ä¸æµ“åº¦ä»¥ç¡®è®¤è¯Šæ–­ã€‚[\[27\]](#cite_note-27)

### ä¾èµ–æ€§å’Œæ»¥ç”¨æ½œåŠ› {#Dependence_and_abuse_potential}

åŠ å·´å–·ä¸ä¸è¢«è®¤ä¸ºå…·æœ‰å¿ƒç†æˆç˜¾æ€§ã€‚ç„¶è€Œï¼Œå‘å±•å‡ºå¯¹è¯¥è¯ç‰©çš„èº«ä½“ä¾èµ–æ˜¯å¯èƒ½çš„ã€‚äº‹å®ä¸Šï¼Œäººä»¬åœ¨åœæ­¢æœç”¨åŠ å·´å–·ä¸åé•¿è¾¾ 45 å¤©å†…å¯èƒ½ä¼šå‡ºç°æˆ’æ–­ç—‡çŠ¶ã€‚è™½ç„¶åŠ å·´å–·ä¸ç¡®å®ç»™ä¸€äº›äººå¸¦æ¥äº†å¯¼è‡´æ»¥ç”¨çš„æ¬£å¿«â€œ[è¯æ•ˆ](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)â€ï¼Œä½†åŠ å·´å–·ä¸æ»¥ç”¨è€…å¹¶æ²¡æœ‰è¡¨ç°å‡ºä¸å…¶ä»–æ›´å¸¸è§çš„[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ï¼ˆå¦‚[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)ã€[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)æˆ–[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ï¼‰ç›¸å…³çš„å¼ºè¿«æ€§å¯»è¯è¡Œä¸ºæˆ–å¼ºçƒˆæ¸´æœ›ã€‚

é•¿æœŸæŒç»­ä½¿ç”¨ä¼šå¯¹[æŠ—ç„¦è™‘](/è¯æ•ˆ/é•‡é™.md)ä½œç”¨äº§ç”Ÿè€å—æ€§ã€‚åœæ­¢ä½¿ç”¨åï¼Œè€å—æ€§ä¼šåœ¨ 7-14 å¤©å†…æ¢å¤åˆ°åŸºçº¿ã€‚åœ¨æ•°å‘¨æˆ–æ›´é•¿æ—¶é—´çš„ç¨³å®šå‰‚é‡åçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æˆ’æ–­ç—‡çŠ¶æˆ–åè·³ç—‡çŠ¶ï¼Œå¯èƒ½éœ€è¦é€æ¸å‡å°‘å‰‚é‡ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨ {#Dangerous_interactions}

*   **[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)** - å°†é˜¿ç‰‡ç±»è¯ç‰©ä¸åŠ å·´å–·ä¸è”ç”¨ä¼šå¯¼è‡´å‘¼å¸è¡°ç«­æ­»äº¡ã€‚
*   **[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) ([GABAèƒ½](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md))** - åŠ å·´å–·ä¸æ˜¾ç€å¢å¼º[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)ã€[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)å’Œå…¶ä»–[GABAèƒ½è¯ç‰©](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)çš„ä½œç”¨ï¼Œè¿™å¯èƒ½å¯¼è‡´æ–­ç‰‡å’Œå±é™©è¡Œä¸ºã€‚

## æ³•å¾‹åœ°ä½ {#Legal_status}

**æ³•å¾‹åœ°ä½éƒ¨åˆ†æ˜¯ä¸€ä¸ª[å°ä½œå“](/æ–‡æ¡£/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md)ã€‚**
*å› æ­¤ï¼Œå®ƒå¯èƒ½åŒ…å«ä¸å®Œæ•´æˆ–é”™è¯¯çš„ä¿¡æ¯ã€‚ä½ å¯ä»¥é€šè¿‡[æ‰©å±•å®ƒ](CONTRIBUTING.md)æ¥æä¾›å¸®åŠ©ã€‚*

åŠ å·´å–·ä¸æ˜¯å¤„æ–¹è¯ï¼Œåªæœ‰åœ¨å’¨è¯¢åŒ»ç”Ÿåæ‰èƒ½å¼€å…·å¤„æ–¹ã€‚

*   **å¾·å›½ï¼š** æ ¹æ® Anlage 1 AMVVï¼ŒåŠ å·´å–·ä¸æ˜¯å¤„æ–¹è¯ã€‚[\[28\]](#cite_note-28)
*   **ç‘å£«ï¼š** åŠ å·´å–·ä¸è¢«åˆ—ä¸º "Abgabekategorie B" è¯ç‰©ï¼Œéœ€è¦å¤„æ–¹ã€‚
*   **è‹±å›½ï¼š** åŠ å·´å–·ä¸å¯å‡­å¤„æ–¹è·å¾—ã€‚[\[29\]](#cite_note-29)
*   **ç¾å›½ï¼š** åŠ å·´å–·ä¸ä¸æ˜¯é™„è¡¨ç‰©è´¨ï¼Œä½†åªèƒ½å‡­å¤„æ–¹å‡ºå”®ã€‚[\[30\]](#cite_note-30)
    *   **ä¾‹å¤–ï¼š** åŠ å·´å–·ä¸åœ¨ä»¥ä¸‹åœ°åŒºæ˜¯é™„è¡¨ V å—æ§ç‰©è´¨ï¼šé˜¿æ‹‰å·´é©¬å·ã€è‚¯å¡”åŸºå·ã€å¯†æ­‡æ ¹å·ã€åŒ—è¾¾ç§‘ä»–å·ã€ç”°çº³è¥¿å·ã€å¼—å‰å°¼äºšå·å’Œè¥¿å¼—å‰å°¼äºšå·ã€‚åœ¨ä»¥ä¸‹åœ°åŒºæœ‰å¤„æ–¹è¯ç›‘æ§ï¼šåº·æ¶…ç‹„æ ¼å·ã€å“¥ä¼¦æ¯”äºšç‰¹åŒºã€å°ç¬¬å®‰çº³å·ã€å ªè¨æ–¯å·ã€é©¬è¨è¯¸å¡å·ã€æ˜å°¼è‹è¾¾å·ã€å†…å¸ƒæ‹‰æ–¯åŠ å·ã€æ–°æ³½è¥¿å·ã€ä¿„äº¥ä¿„å·ã€ä¿„å‹’å†ˆå·ã€çŠ¹ä»–å·å’Œæ€€ä¿„æ˜å·ã€‚[\[31\]](#cite_note-31)

## å¦è§ {#See_also}

*   [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)
*   [æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)
*   [è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)
*   [GABA](/æ–‡æ¡£/å…³äºæœ¬ç«™/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)
*   [æ™®ç‘å·´æ—](/è¯ç‰©/æ™®ç‘å·´æ—.md)
*   [è²å°¼å¸ƒç‰¹](/è¯ç‰©/è²å°¼å¸ƒç‰¹.md)

## å¤–éƒ¨é“¾æ¥ {#External_links}

*   [Gabapentin (Wikipedia)](https://en.wikipedia.org/wiki/Gabapentin)
*   [Gabapentin (Erowid Vault)](https://www.erowid.org/pharms/gabapentin/)
*   [Gabapentin (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=8697)
*   [Gabapentin (DrugBank)](https://go.drugbank.com/drugs/DB00996)
*   [Gabapentin (Drugs.com)](https://www.drugs.com/gabapentin.html)
*   [Gabapentin (Drugs-Forum)](https://drugs-forum.com/wiki/Gabapentin)

## å‚è€ƒæ–‡çŒ® {#References}

1. [â†‘](#cite_ref-tripsit_1-0) [*Risks of Combining Depressants \- TripSit*](https://tripsit.me/combining-depressants/)
2. â†‘ [2.0](#cite_ref-NeurotoninMedScape_2-0) [2.1](#cite_ref-NeurotoninMedScape_2-1) [*Neurontin, Gralise (gabapentin) dosing, indications, interactions, adverse effects, and more*](https://reference.medscape.com/drug/neurontin-gralise-gabapentin-343011)
3. [â†‘](#cite_ref-CalandreRico-Villademoros2016_3-0) Calandre, Elena P.; Rico\-Villademoros, Fernando; Slim, Mahmoud (2016\). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". *Expert Review of Neurotherapeutics*. **16** (11\): 1263â€“1277\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1080/14737175\.2016\.1202764](//doi.org/10.1080%2F14737175.2016.1202764). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1473\-7175](//www.worldcat.org/issn/1473-7175).
4. [â†‘](#cite_ref-4) Schatzberg, A. F., Cole, J. O., DeBattista, C. (2010\). *Manual of Clinical Psychopharmacology*. American Psychiatric Pub. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9781585623778](http://en.wikipedia.org/wiki/Special:BookSources/9781585623778 "wikipedia:Special:BookSources/9781585623778").
5. [â†‘](#cite_ref-5) Sobel, S. V. (5 November 2012\). *Successful Psychopharmacology: Evidence\-Based Treatment Solutions for Achieving Remission*. W. W. Norton \& Company. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780393708578](http://en.wikipedia.org/wiki/Special:BookSources/9780393708578 "wikipedia:Special:BookSources/9780393708578").
6. [â†‘](#cite_ref-6) Richards, D., Aronson, J., Coleman, J., Reynolds, D. J. (10 November 2011\). *Oxford Handbook of Practical Drug Therapy*. OUP Oxford. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780199562855](http://en.wikipedia.org/wiki/Special:BookSources/9780199562855 "wikipedia:Special:BookSources/9780199562855").
7. [â†‘](#cite_ref-7) Mula, M., Pini, S., Cassano, G. B. (June 2007\). "The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence". *Journal of Clinical Psychopharmacology*. **27** (3\): 263â€“272\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1097/jcp.0b013e318059361a](//doi.org/10.1097%2Fjcp.0b013e318059361a). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0271\-0749](//www.worldcat.org/issn/0271-0749).
8. [â†‘](#cite_ref-8) Hamer, A. M., Haxby, D. G., McFarland, B. H., Ketchum, K. (July 2002\). ["Gabapentin Use in a Managed Medicaid Population"](https://www.jmcp.org/doi/abs/10.18553/jmcp.2002.8.4.266). *Journal of Managed Care Pharmacy*. **8** (4\): 266â€“271\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.18553/jmcp.2002\.8\.4\.266](//doi.org/10.18553%2Fjmcp.2002.8.4.266). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1083\-4087](//www.worldcat.org/issn/1083-4087).
9. [â†‘](#cite_ref-9) Steinman, M. A., Bero, L. A., Chren, M.\-M., Landefeld, C. S. (15 August 2006\). ["Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents"](https://www.acpjournals.org/doi/10.7326/0003-4819-145-4-200608150-00008). *Annals of Internal Medicine*. **145** (4\): 284â€“293\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.7326/0003\-4819\-145\-4\-200608150\-00008](//doi.org/10.7326%2F0003-4819-145-4-200608150-00008). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0003\-4819](//www.worldcat.org/issn/0003-4819).
10. [â†‘](#cite_ref-10) Wijemanne, S., Jankovic, J. (1 June 2015\). ["Restless legs syndrome: clinical presentation diagnosis and treatment"](https://www.sciencedirect.com/science/article/pii/S1389945715006474). *Sleep Medicine*. **16** (6\): 678â€“690\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.sleep.2015\.03\.002](//doi.org/10.1016%2Fj.sleep.2015.03.002). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1389\-9457](//www.worldcat.org/issn/1389-9457).
11. [â†‘](#cite_ref-11) Attal, N., Cruccu, G., Baron, R., HaanpÃ¤Ã¤, M., Hansson, P., Jensen, T. S., Nurmikko, T. (September 2010\). "EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision". *European Journal of Neurology*. **17** (9\): 1113â€“e88\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1111/j.1468\-1331\.2010\.02999\.x](//doi.org/10.1111%2Fj.1468-1331.2010.02999.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1468\-1331](//www.worldcat.org/issn/1468-1331).
12. [â†‘](#cite_ref-12) Wyllie, E. (2012\). *Wyllieâ€™s treatment of epilepsy: principles and practice*. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9781451153484](http://en.wikipedia.org/wiki/Special:BookSources/9781451153484 "wikipedia:Special:BookSources/9781451153484").
13. [â†‘](#cite_ref-13) Sneader, W. (2005\). [*Drug Discovery A History*](https://nbn-resolving.org/urn:nbn:de:101:1-201412158328). [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780470015520](http://en.wikipedia.org/wiki/Special:BookSources/9780470015520 "wikipedia:Special:BookSources/9780470015520").
14. [â†‘](#cite_ref-14) Levandovskiy, I. A., Sharapa, D. I., Shamota, T. V., Rodionov, V. N., Shubina, T. E. (February 2011\). ["Conformationally restricted GABA analogs: from rigid carbocycles to cage hydrocarbons"](https://www.future-science.com/doi/10.4155/fmc.10.287). *Future Medicinal Chemistry*. **3** (2\): 223â€“241\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.4155/fmc.10\.287](//doi.org/10.4155%2Ffmc.10.287). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1756\-8919](//www.worldcat.org/issn/1756-8919).
15. [â†‘](#cite_ref-15) Taylor, C. P. (1997\). "Mechanisms of action of gabapentin". *Revue Neurologique*. 153 Suppl 1: S39â€“45\. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0035\-3787](//www.worldcat.org/issn/0035-3787).
16. [â†‘](#cite_ref-16) Cai, K., Nanga, R. P., Lamprou, L., Schinstine, C., Elliott, M., Hariharan, H., Reddy, R., Epperson, C. N. (December 2012\). ["The Impact of Gabapentin Administration on Brain GABA and Glutamate Concentrations: A 7T 1H\-MRS Study"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499716/). *Neuropsychopharmacology*. **37** (13\): 2764â€“2771\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1038/npp.2012\.142](//doi.org/10.1038%2Fnpp.2012.142). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0893\-133X](//www.worldcat.org/issn/0893-133X).
17. [â†‘](#cite_ref-17) Sills, G. J. (February 2006\). "The mechanisms of action of gabapentin and pregabalin". *Current Opinion in Pharmacology*. **6** (1\): 108â€“113\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.coph.2005\.11\.003](//doi.org/10.1016%2Fj.coph.2005.11.003). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1471\-4892](//www.worldcat.org/issn/1471-4892).
18. [â†‘](#cite_ref-18) Neurontin Clinical Pharmacology Biopharmaceutics Review \| <http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-397.pdf_Neurontin_BioPharmr.pdf>
19. [â†‘](#cite_ref-19) Manville, R. W., Abbott, G. W. (1 October 2018\). ["Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels"](https://molpharm.aspetjournals.org/content/94/4/1155). *Molecular Pharmacology*. **94** (4\): 1155â€“1163\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1124/mol.118\.112953](//doi.org/10.1124%2Fmol.118.112953). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0026\-895X](//www.worldcat.org/issn/0026-895X).
20. [â†‘](#cite_ref-20) [*gabapentin, Michigan Medicine*](https://www.uofmhealth.org/health-library/d03182a1)
21. â†‘ [21.0](#cite_ref-Patorno2010_21-0) [21.1](#cite_ref-Patorno2010_21-1) [21.2](#cite_ref-Patorno2010_21-2) Patorno, E., Bohn, R. L., Wahl, P. M., Avorn, J., Patrick, A. R., Liu, J., Schneeweiss, S. (14 April 2010\). "Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death". *JAMA*. **303** (14\): 1401â€“1409\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1001/jama.2010\.410](//doi.org/10.1001%2Fjama.2010.410). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1538\-3598](//www.worldcat.org/issn/1538-3598).
22. [â†‘](#cite_ref-22) <http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020235s041,020882s028,021129s027lbl.pdf>
23. [â†‘](#cite_ref-23) Aronson, J. K. (4 March 2014\). *Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions*. Newnes. [ISBN](http://en.wikipedia.org/wiki/International_Standard_Book_Number "wikipedia:International Standard Book Number") [9780444626363](http://en.wikipedia.org/wiki/Special:BookSources/9780444626363 "wikipedia:Special:BookSources/9780444626363").
24. [â†‘](#cite_ref-24) <http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020235s057,020882s041,021129s039lbl.pdf>
25. [â†‘](#cite_ref-25) <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100190.htm>
26. [â†‘](#cite_ref-26) Patorno, E., Bohn, R. L., Wahl, P. M., Avorn, J., Patrick, A. R., Liu, J., Schneeweiss, S. (14 April 2010\). ["Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, or Violent Death"](https://doi.org/10.1001/jama.2010.410). *JAMA*. **303** (14\): 1401â€“1409\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1001/jama.2010\.410](//doi.org/10.1001%2Fjama.2010.410). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [0098\-7484](//www.worldcat.org/issn/0098-7484).
27. [â†‘](#cite_ref-27) R.C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 677â€“8\. ISBN 978\-0\-9626523\-7\-0\.
28. [â†‘](#cite_ref-28) [*AMVV \- Verordnung Ã¼ber die Verschreibungspflicht von Arzneimitteln*](https://www.gesetze-im-internet.de/amvv/BJNR363210005.html)
29. [â†‘](#cite_ref-29) [Baclofen: muscle relaxant that relieves muscle spasms \- NHS](https://www.nhs.uk/medicines/baclofen/about-baclofen/)
30. [â†‘](#cite_ref-30) Peckham, A. M., Ananickal, M. J., Sclar, D. A. (17 August 2018\). ["Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance"](https://www.dovepress.com/gabapentin-use-abuse-and-the-us-opioid-epidemic-the-case-for-reclassif-peer-reviewed-fulltext-article-RMHP). *Risk Management and Healthcare Policy*. **11**: 109â€“116\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.2147/RMHP.S168504](//doi.org/10.2147%2FRMHP.S168504).
31. [â†‘](#cite_ref-31) Collins, S. (October 2021\). ["More states make gabapentin a Schedule V Controlled Substance"](https://linkinghub.elsevier.com/retrieve/pii/S1042099121007301). *Pharmacy Today*. **27** (10\): 33\. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10\.1016/j.ptdy.2021\.09\.016](//doi.org/10.1016%2Fj.ptdy.2021.09.016). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number") [1042\-0991](//www.worldcat.org/issn/1042-0991).